Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Jaktinib in Active Ankylosing Spondylitis
NCT05861128Phase 3Completed
- Sponsor
- Zelgen
- Start
- Nov 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of jaktinib in ankylosing spondylitis (AS), sponsored by Zelgen. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Related Discontinuations at 32 weeks. Started Nov 2023; status: completed.
02
Drugs
jaktinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05861128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861128.